Literature DB >> 33947834

Moderate DNA hypomethylation suppresses intestinal tumorigenesis by promoting caspase-3 expression and apoptosis.

Xiaoya Duan1, Yuanyong Huang1, Xiaoxing Chen1, Wencai Wang1, Jiwei Chen1, Jialun Li1, Wei Yang1, Jiwen Li1, Qihan Wu2, Jiemin Wong3,4.   

Abstract

Global DNA hypomethylation is a most common epigenetic alteration in human neoplasia. However, accumulative evidence shows that global DNA hypomethylation impacts tumorigenesis in a tissue-specific manner, promoting tumorigenesis in some but suppressing tumorigenesis in others including colorectal cancer. The underlying mechanisms, especially how DNA hypomethylation suppresses tumorigenesis, remain largely unknown. Here, we investigate how DNA hypomethylation affects intestinal tumorigenesis by using an Uhrf1 tandem tudor domain knockin mutant mouse model (Uhrf1ki/ki) that exhibits a moderate ~10% reduction of global DNA methylation. We found that both chemical-induced colorectal carcinogenesis and Apc loss of heterozygosity (LOH)-induced intestinal tumorigenesis are substantially suppressed in the Uhrf1 mutant mice. Furthermore, unlike Dnmt1 hypomorphic mice in which DNA hypomethylation suppresses the incidence of macroscopic intestinal tumors but promotes the formation of microadenoma in ApcMin/+ background, Uhrf1ki/ki/ApcMin/+ mice have markedly reduced incidence of both microadenoma and macroadenoma. DNA hypomethylation does not appear to affect Apc LOH, activation of the Wnt or Hippo pathway, or tumor cell proliferation, but acts cooperatively with activated Wnt pathway to enhance the caspase-3 gene expression, activation, and apoptosis. Furthermore, increased caspase-3 expression correlates with DNA hypomethylation within the caspase-3 enhancer regions. Taken together, we present a new mouse model for investigating the role of and the molecular mechanisms by which DNA hypomethylation suppresses intestinal tumorigenesis. Our finding that a moderate DNA hypomethylation is sufficient to suppress intestinal tumorigenesis by promoting caspase-3 expression and apoptosis sheds new light on DNA-methylation inhibitor-based colorectal cancer therapeutics.

Entities:  

Year:  2021        PMID: 33947834     DOI: 10.1038/s41389-021-00328-9

Source DB:  PubMed          Journal:  Oncogenesis        ISSN: 2157-9024            Impact factor:   7.485


  64 in total

Review 1.  DNA methylation and cancer.

Authors:  Marta Kulis; Manel Esteller
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

Review 2.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Induction of tumors in mice by genomic hypomethylation.

Authors:  François Gaudet; J Graeme Hodgson; Amir Eden; Laurie Jackson-Grusby; Jessica Dausman; Joe W Gray; Heinrich Leonhardt; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 4.  DNA methylation and cancer.

Authors:  Phillippa C Taberlay; Peter A Jones
Journal:  Prog Drug Res       Date:  2011

5.  DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair.

Authors:  Binh N Trinh; Tiffany I Long; Andrea E Nickel; Darryl Shibata; Peter W Laird
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 6.  DNA methylation and cancer.

Authors:  P W Laird; R Jaenisch
Journal:  Hum Mol Genet       Date:  1994       Impact factor: 6.150

Review 7.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host.

Authors:  Winston Timp; Andrew P Feinberg
Journal:  Nat Rev Cancer       Date:  2013-06-13       Impact factor: 60.716

Review 8.  DNA methylation and cancer development: molecular mechanism.

Authors:  Haleh Akhavan-Niaki; Ali Akbar Samadani
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

9.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts.

Authors:  A P Feinberg; B Vogelstein
Journal:  Nature       Date:  1983-01-06       Impact factor: 49.962

Review 10.  DNA methylation in cancer: too much, but also too little.

Authors:  Melanie Ehrlich
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

View more
  1 in total

1.  IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Jie-Ru Yang; Ju Wang; Hai-Ming Li; Shuai Gao; Yu-Chen Fan; Kai Wang
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.